The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • msage@programming.dev
    1·
    14 hours ago

    I have no issue with that, but let’s not act like there was anything else other than a trend.

    If people said ‘I got caught up in the moment, everyone was doing it’ then fine, you got duped, it happens.

    But don’t give me lame excuses. Most people didn’t approach it critically, which is not unusual, but own up to it.

    I’m tired of the same excuse over and over.

    And those tests weren’t even that cheap.